Oncolytics Biotech(NASDAQ) ONCY

Market Cap$79.50M

Since IPO (2001)-98%

5 Year-67%

1 Year-27%

1 Month-16%

$0.75

-5.14%

-0.04Today

Oncolytics Biotech last closing stock price
Metric	Price	Date
Last close	USD 0.79	2026-07-28

Oncolytics Biotech stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-7.73%	USD 0.86	2026-07-21
1 month	-16.43%	USD 0.95	2026-06-26
3 month	-9.06%	USD 0.87	2026-04-29
Year to date	-9.37%	USD 0.87	2025-12-31
1 year	-27.33%	USD 1.09	2025-07-28
3 year	-71.81%	USD 2.81	2023-07-28
5 year	-66.72%	USD 2.38	2021-07-29
Since inception	-98.38%	USD 48.93	2001-10-05

Oncolytics Biotech Financials at a Glance

Market Cap

$79.50M

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$35.52M

EPS (TTM)

-$0.25

P/E Ratio

-3.15

Dividend

$0.00

Beta (Volatility)

0.96 (Low)

Dividend

$0.00

Beta (Volatility)

0.96 (Low)

Price

$0.75

Volume

907,580

Open

$0.78

Price

$0.75

Volume

907,580

Open

$0.78

Previous Close

$0.75

Daily Range

$0.75 - $0.79

52-Week Range

$0.75 - $1.51

Estimated Earnings Date

Aug 14, 2026

Dividend

$0.00

Beta (Volatility)

0.96 (Low)

Price

$0.75

Volume

907,580

Open

$0.78

Previous Close

$0.75

Daily Range

$0.75 - $0.79

52-Week Range

$0.75 - $1.51

Estimated Earnings Date

Aug 14, 2026

ONCY News

This High-Risk, High-Reward Biotech Is Worth a Look

Sean WilliamsJun 25, 2013

Can Financial Innovation Unlock a Cure for Cancer?

Maxx ChatskoMay 22, 2013

These 3 Stocks Aren't as Wobbly as They Appear

Rich DupreyFeb 21, 2013

Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Oncolytics Biotech

Oncolytics Biotech develops medicines for cancer patients with few treatment options. Its main product, pelareorep, aims to help the immune system fight tumors. The company works with partners to test new cancer therapies in clinical trials.

Products and Services

Pelareorep (lead candidate): An intravenous therapy using a virus to stimulate the immune system against cancer; targets patients with solid tumors and blood cancers. (0% of revenue; company is pre-revenue)
Clinical Trial Programs: Focused on gastrointestinal cancers, including colorectal, anal, and pancreatic cancers; serves patients with advanced disease. (0% of revenue)
Combination Therapy Research: Studies pelareorep with other drugs, such as chemotherapy and immunotherapy, for broader cancer treatment options. (0% of revenue)
Strategic Collaborations: Works with large pharmaceutical companies to develop and test new cancer treatments. (0% of revenue)

Growth and Expansion

Formed co-development agreements with Merck KGaA and Pfizer in 2022 for breast cancer trials.
Launched new clinical studies in colorectal and pancreatic cancers in 2025 and 2026.
Expanded manufacturing capacity and validated production processes in 2025.
Secured a supply agreement with Roche for immunotherapy drug in 2025.
Raised new capital through equity offerings in 2025 and early 2026.

What Makes Oncolytics Biotech Stand Out

Oncolytics Biotech holds 137 patents worldwide, supporting its proprietary cancer therapy platform. The company’s approach targets specific tumor types and combines with other treatments for potential broader use. Strategic partnerships help advance clinical development and prepare for possible commercialization.

Five Things You Need to Know

No revenue in 2025, 2024, or 2023; company remains pre-commercial.
Net loss was $28.8 million in 2025, up 26% from 2024.
Cash and equivalents were $5.2 million at December 31, 2025, down 53% year-over-year.
Raised $14.1 million from financing activities in 2025 to fund operations.
R&D expenses fell 13.8% in 2025, while general expenses rose 52.6% year-over-year.

Bottom Line

Oncolytics Biotech focuses on developing new cancer therapies and relies on partnerships and external funding. The company’s future depends on clinical trial progress and securing additional capital.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Jared Kelly

Website

www.oncolyticsbiotech.com

Headquarters

San Diego, CA 92121, US

ONCY Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

5214.36%

Return on Capital

N/A

Return on Assets

-435.28%

Earnings Yield

-31.75%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$79.50M

Shares Outstanding

100.36M

Volume

907.58K

Avg. Volume

1.42M

Financials (TTM)

Gross Profit

-CA$119.31K

Operating Income

-CA$35.48M

EBITDA

-CA$36.08M

Operating Cash Flow

-CA$30.89M

Capital Expenditure

-CA$15.65K

Free Cash Flow

-CA$30.89M

Cash & ST Invst.

CA$5.49M

Total Debt

CA$508.00K

Oncolytics Biotech Performance Analysis

Oncolytics Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	CAD 0	N/A
2023	2023-12-31	CAD 0	N/A
2024	2024-12-31	CAD 0	N/A
2025	2025-12-31	CAD 0	N/A

Oncolytics Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	N/A
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A

Oncolytics Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	CAD -0.33	-16.2%
2023	2023-12-31	CAD -0.30	-7.5%
2024	2024-12-31	CAD -0.30	-2.0%
2025	2025-12-31	CAD -0.30	0.7%

Oncolytics Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	14.3%
Q3	2025-09-30	-106.8%
Q4	2025-12-31	86.4%
Q1	2026-03-31	-475.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

-CA$22.31K

-17.4%

Gross Margin

0.00%

N/A

Market Cap

$79.50M

N/A

Market Cap/Employee

$2.74M

N/A

Employees

N/A

Net Income

-CA$12.89M

-92.8%

EBITDA

-CA$12.92M

-87.2%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

CA$5.49M

-64.1%

Total Debt

CA$508.00K

-49.2%

Accounts Receivable

CA$961.00K

+979.8%

Inventory

CA$0.00

N/A

Long Term Debt

CA$342.00K

-51.8%

Short Term Debt

CA$166.00K

-42.8%

Return on Assets

-4.35%

N/A

Return on Invested Capital

-12.96%

N/A

Free Cash Flow

-CA$10.17M

-56.5%

Operating Cash Flow

-CA$10.17M

-56.5%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

COYACoya Therapeutics, Inc.

COYACoya Therapeutics, Inc.$3.87-3.25%

TILInstil Bio, Inc.

TILInstil Bio, Inc.$7.22-0.96%

CLNNClene Inc.

CLNNClene Inc.$4.72-5.41%

TVGNTevogen Bio Holdings Inc.

TVGNTevogen Bio Holdings Inc.$5.94+6.26%

ATOSAtossa Therapeutics, Inc.

ATOSAtossa Therapeutics, Inc.$2.31-4.35%

SRZNSurrozen, Inc.

SRZNSurrozen, Inc.$19.20-1.03%

WHWKWhitehawk Therapeutics Inc

WHWKWhitehawk Therapeutics Inc$3.66-0.54%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$8.41-0.06%

TAT&T

TAT&T$23.94-0.03%

SMRNuScale Power

SMRNuScale Power$7.59-0.08%

ORCLOracle

ORCLOracle$117.74-0.02%

CMGChipotle Mexican Grill

CMGChipotle Mexican Grill$34.24+0.02%

CVNACarvana

CVNACarvana$66.32+0.00%

SGOViShares Trust - iShares 0-3 Month Treasury Bond ETF

SGOViShares Trust - iShares 0-3 Month Treasury Bond ETF$100.68+0.00%

Questions About ONCY

What is the current price of Oncolytics Biotech?

Oncolytics Biotech is trading at $0.75 per share.

What is the 52-week range for Oncolytics Biotech?

Over the past 52 weeks, Oncolytics Biotech has traded between $0.75 and $1.51.

How much debt does Oncolytics Biotech have?

As of the most recent reporting period, Oncolytics Biotech reported total debt of CA$508.00K.

How much cash does Oncolytics Biotech have on hand?

Oncolytics Biotech reported CA$5.49M in cash and cash equivalents in its most recent financial results.

What is Oncolytics Biotech’s dividend yield?

Oncolytics Biotech does not currently have a dividend yield.

Oncolytics Biotech(NASDAQ) ONCY

Oncolytics Biotech Financials at a Glance

ONCY News

This High-Risk, High-Reward Biotech Is Worth a Look

A New Cancer-Killing Virus

Can Financial Innovation Unlock a Cure for Cancer?

These 3 Stocks Aren't as Wobbly as They Appear

This Week in Biotech

3 Humongous Health-Care Stocks This Week

Oncolytics Presents Promising Phase 1 Data in Colorectal Cancer

Could a Virus Make You Lots of Money?

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Oncolytics Biotech

Products and Services

Growth and Expansion

What Makes Oncolytics Biotech Stand Out

Five Things You Need to Know

Bottom Line

ONCY Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Oncolytics Biotech Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ONCY

What is the current price of Oncolytics Biotech?

What is the 52-week range for Oncolytics Biotech?

How much debt does Oncolytics Biotech have?

How much cash does Oncolytics Biotech have on hand?

What is Oncolytics Biotech’s dividend yield?

Premium Investing Services